STAT

We’re learning a lot about the coronavirus. It will help us assess risk

We need to learn a lot more about the coronavirus. But we're already learned a lot — and it will help us assess risk.
The coronavirus that causes Covid-19.

It has been two months since China announced a previously unknown virus had been identified as the cause of a new outbreak in the city of Wuhan. In the weeks since then, the coronavirus — now called SARS-CoV2 — has raced around the globe, igniting major outbreaks in Iran, South Korea, Italy, Japan and now, it seems, Seattle.

There are still many, many questions about this virus and the disease it causes, Covid-19. But in a matter of mere weeks, a number of features of the disease have come into focus, through extraordinarily rapid sharing of research.

“Eight weeks into Covid-19, there’s quite a lot that we are learning,” Maria Van Kerkhove, who heads the World Health Organization’s emerging diseases and zoonoses unit, said in a recent interview. (Zoonoses are diseases that jump to people from animals.)

Kerkhove spoke to STAT after returning to the agency’s headquarters in Geneva after two weeks in China, where she was part of an international mission to learn about China’s response to its outbreak.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks